Enhanced antibacterial effect of ceftriaxone sodium-loaded chitosan nanoparticles against intracellular Salmonella typhimurium

AAPS PharmSciTech

Volumn 13, Issue 2, 2012, Pages 411-421

  Zaki, Noha M ^a,b   Hafez, Mohamed M ^a  

^a TAIF UNIVERSITY   (Saudi Arabia)

^b African Union Organization St Abbassia   (Egypt)

Author keywords

ceftriaxone sodium; chitosan nanoparticles; enterocytes; intracellular delivery; macrophages

Indexed keywords

CEFTRIAXONE; CHITOSAN; NANOPARTICLE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BIOCOMPATIBILITY; BLOOD COMPATIBILITY; CELL STRAIN CACO 2; CELL VIABILITY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DISPERSION; DRUG DELIVERY SYSTEM; DRUG RELEASE; ENDOSOME; IN VITRO STUDY; INTRACELLULAR BACTERIUM; MICROFLUOROMETRY; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REDUCTION; SALMONELLA TYPHIMURIUM; ZETA POTENTIAL;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CEFTRIAXONE; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; CYTOPHOTOMETRY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; HEMOLYSIS; HUMANS; INHIBITORY CONCENTRATION 50; INTESTINAL MUCOSA; MACROPHAGES; MICE; MICROSCOPY, CONFOCAL; NANOPARTICLES; NANOTECHNOLOGY; PARTICLE SIZE; PERMEABILITY; SALMONELLA TYPHIMURIUM; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 84862855871     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-012-9758-7     Document Type: Article

References (73)

1. TC Eickhoff J Ehret 1981 Comparative in vitro studies of Ro 13-9904, a new cephalosporin derivative Antimicrob Agents Chemother 19 3 435 442 6264845 1:CAS:528:DyaL3MXhs1ymtrk%3D (Pubitemid 11119388)
2. PA Anton JA Kemp T Butler MR Jacobs 1982 Comparative efficacies of ceftriaxone, moxalactam, and ampicillin in experimental Salmonella typhimurium infection Antimicrob Agents Chemother 22 2 312 315 6100426 1:CAS:528: DyaL38Xlt1Siu74%3D (Pubitemid 12020126)
3. SL Keenholtz NV Jacobus FP Tally SL Gorbach 1983 In vitro activity of ceftazidime and ceftriaxone Clin Ther 5 6 603 616 6313195 1:STN:280: DyaL2c%2Fis1ejsQ%3D%3D (Pubitemid 13018684)
4. HC Neu NJ Meropol KP Fu 1981 Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin Antimicrob Agents Chemother 19 3 414 423 6972729 1:CAS:528:DyaL3MXhs1ymtrg%3D (Pubitemid 11119385)
5. H Kuhn P Angehrn L Havas 1986 Autoradiographic evidence for penetration of 3H-ceftriaxone (Rocephin) into cells of spleen, liver and kidney of mice Chemotherapy 32 2 102 112 3698722 10.1159/000238398 1:CAS:528:DyaL28Xht1amtLw%3D (Pubitemid 16135632)
6. G Beskid JG Christenson R Cleeland W DeLorenzo PW Trown 1981 In vivo activity of ceftriaxone (Ro 13-9904), a new broad-spectrum semisynthetic cephalosporin Antimicrob Agents Chemother 20 2 159 167 6269487 1:CAS:528:DyaL3MXlt1KisL8%3D (Pubitemid 11015122)
7. BC Lemaitre DA Mazigh MR Scavizzi 1991 Failure of beta-lactam antibiotics and marked efficacy of fluoroquinolones in treatment of murine Yersinia pseudotuberculosis infection Antimicrob Agents Chemother 35 9 1785 1790 1952849 1:CAS:528:DyaK3MXlslCit70%3D
8. M Maurin NF Mersali D Raoult 2000 Bactericidal activities of antibiotics against intracellular Francisella tularensis Antimicrob Agents Chemother 44 12 3428 3431 11083651 10.1128/AAC.44.12.3428-3431.2000 1:CAS:528: DC%2BD3MXhs1KitLk%3D (Pubitemid 33009505)
9. CH Chiu TY Lin JT Ou 1999 In vitro evaluation of intracellular activity of antibiotics against non-typhoid Salmonella Int J Antimicrob Agents 12 1 47 52 10389647 10.1016/S0924-8579(99)00038-2 1:CAS:528:DyaK1MXjvVemtrc%3D (Pubitemid 29241824)
10. Moulin F, Sauve-Martin H, Marc E, Lorrot M, Soulier M, Ravilly S, et al. Ciprofloxacin after clinical failure of ceftriaxone for severe salmonellosis in children. Internet J Infect Dis. 2003;3.
11. CA Lipinski F Lombardo BW Dominy PJ Feeney 2001 Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv Drug Deliv Rev 46 1-3 3 26 11259830 10.1016/S0169-409X(00)00129-0 1:CAS:528:DC%2BD3MXitVOhs7o%3D (Pubitemid 33653411)
12. S Lee SK Kim DY Lee SY Chae Y Byun 2006 Pharmacokinetics of a new, orally available ceftriaxone formulation in physical complexation with a cationic analogue of bile acid in rats Antimicrob Agents Chemother 50 5 1869 1871 16641464 10.1128/AAC.50.5.1869-1871.2006 1:CAS:528:DC%2BD28XksVKktbc%3D
13. Y Mrestani C Mrestani-Klaus B Bretschneider RH Neubert 2004 Improvement of lipophilicity and membrane transport of cefuroxime using in vitro models Eur J Pharm Biopharm 58 3 653 657 15451541 10.1016/j.ejpb.2004.04.008 1:CAS:528:DC%2BD2cXnvFagurg%3D (Pubitemid 39297113)
14. Y Mrestani A Hartl RH Neubert 2006 Influence of absorption enhancers on the pharmacokinetic properties of non-oral beta-lactam-cefpirom using the rabbit (Chinchilla) in vivo model Int J Pharm 309 1-2 67 70 16377108 10.1016/j.ijpharm.2005.11.017 1:CAS:528:DC%2BD28XnvVWmsg%3D%3D (Pubitemid 43129466)
15. Y Mrestani B Bretschneider A Hartl RH Neubert 2003 In-vitro and in-vivo studies of cefpirom using bile salts as absorption enhancers J Pharm Pharmacol 55 12 1601 1606 14738584 10.1211/0022357022214 1:CAS:528:DC%2BD2cXnslKmtw%3D%3D (Pubitemid 38054389)
16. Y Mrestani B Bretschneider A Hartl M Brandsch RH Neubert 2004 Influence of enhancers on the absorption and on the pharmacokinetics of cefodizime using in-vitro and in-vivo models J Pharm Pharmacol 56 4 485 493 15099444 10.1211/0022357023187 1:CAS:528:DC%2BD2cXkt1erurc%3D (Pubitemid 38455614)
17. S Lee SK Kim DY Lee K Park TS Kumar SY Chae, et al. 2005 Cationic analog of deoxycholate as an oral delivery carrier for ceftriaxone J Pharm Sci 94 11 2541 2548 16200559 10.1002/jps.20478 1:CAS:528:DC%2BD2MXht1Ogur7O (Pubitemid 43081950)
18. SW Cho JS Lee SH Choi 2004 Enhanced oral bioavailability of poorly absorbed drugs. I. Screening of absorption carrier for the ceftriaxone complex J Pharm Sci 93 3 612 620 14762900 10.1002/jps.10563 1:CAS:528: DC%2BD2cXitV2lsLg%3D (Pubitemid 38332294)
19. E Briones CI Colino JM Lanao 2008 Delivery systems to increase the selectivity of antibiotics in phagocytic cells J Control Release 125 3 210 227 18077047 10.1016/j.jconrel.2007.10.027 1:CAS:528:DC%2BD1cXhtVGjtLw%3D
20. MC Nacucchio PH Di Rocco DO Sordelli 1990 Liposomes as carriers for antibiotics Targeted Diagn Ther 3 337 354 2131016 1:STN:280: DyaK38%2Fjt1ygsg%3D%3D
21. Q Zhang GT Liao DP Wei CJ Zhang 1996 Increase of gentamicin uptake in cultured mouse peritoneal macrophage and rat hepatocytes when used in the form of nanoparticles Yao Xue Xue Bao 31 5 375 380 9275716 1:CAS:528:DyaK2sXltFan (Pubitemid 126436245)
22. IA Bakker-Woudenberg 1995 Delivery of antimicrobials to infected tissue macrophages Adv Drug Deliv Rev 17 5 20 10.1016/0169-409X(95)00037-8 1:CAS:528:DyaK2MXps1Wltbs%3D
23. P Couvreur E Fattal A Andremont 1991 Liposomes and nanoparticles in the treatment of intracellular bacterial infections Pharm Res 8 9 1079 1086 1788152 10.1023/A:1015885814417 1:CAS:528:DyaK3MXmtl2gtbc%3D
24. C Gamazo S Prior M Concepcion Lecaroz AI Vitas MA Campanero G Perez, et al. 2007 Biodegradable gentamicin delivery systems for parenteral use for the treatment of intracellular bacterial infections Expert Opin Drug Deliv 4 6 677 688 17970669 10.1517/17425247.4.6.677 1:CAS:528:DC%2BD2sXht1elsrrO (Pubitemid 350193402)
25. MC Lecaroz MJ Blanco-Prieto MA Campanero H Salman C Gamazo 2007 Poly(D, L-lactide-coglycolide) particles containing gentamicin: pharmacokinetics and pharmacodynamics in Brucella melitensis-infected mice Antimicrob Agents Chemother 51 4 1185 1190 17220415 10.1128/AAC.00809-06 1:CAS:528: DC%2BD2sXktlOjsbY%3D (Pubitemid 46586792)
26. O Balland H Pinto-Alphandary A Viron E Puvion A Andremont P Couvreur 1996 Intracellular distribution of ampicillin in murine macrophages infected with Salmonella typhimurium and treated with (3H)ampicillin-loaded nanoparticles J Antimicrob Chemother 37 1 105 115 8647751 10.1093/jac/37.1.105 1:CAS:528:DyaK28XhtVaitrw%3D
27. MM Gaspar A Cruz AG Fraga AG Castro ME Cruz J Pedrosa 2008 Developments on drug delivery systems for the treatment of mycobacterial infections Curr Top Med Chem 8 7 579 591 18473884 10.2174/156802608783955629 1:CAS:528: DC%2BD1cXkt1amsLg%3D (Pubitemid 351982581)
28. C Lecaroz C Gamazo MJ Blanco-Prieto 2006 Nanocarriers with gentamicin to treat intracellular pathogens J Nanosci Nanotechnol 6 9-10 3296 3302 17048550 10.1166/jnn.2006.478 1:CAS:528:DC%2BD28XhtVKnsrvJ (Pubitemid 44580014)
29. VP Torchilin 2006 Multifunctional nanocarriers Adv Drug Deliv Rev 58 14 1532 1555 17092599 10.1016/j.addr.2006.09.009 1:CAS:528:DC%2BD28Xht1KmtLbF (Pubitemid 44822608)
30. C Lecaroz MJ Blanco-Prieto MA Burrell C Gamazo 2006 Intracellular killing of Brucella melitensis in human macrophages with microsphere-encapsulated gentamicin J Antimicrob Chemother 58 3 549 556 16799160 10.1093/jac/dkl257 1:CAS:528:DC%2BD28Xotl2ltLw%3D (Pubitemid 44288118)
31. C Lecaroz C Gamazo MJ Renedo MJ Blanco-Prieto 2006 Biodegradable micro- and nanoparticles as long-term delivery vehicles for gentamicin J Microencapsul 23 7 782 792 17123922 10.1080/02652040600946886 1:CAS:528:DC%2BD2sXjsFektA%3D%3D (Pubitemid 44811441)
32. E Lu S Franzblau HCP Onyuksel 2009 Preparation of aminoglycoside-loaded chitosan nanoparticles using dextran sulphate as a counterion J Microencapsul 26 4 346 354 18726818 10.1080/02652040802365182 1:CAS:528:DC%2BD1MXotFykur8%3D
33. M Huang E Khor LY Lim 2004 Uptake and cytotoxicity of chitosan molecules and nanoparticles: effects of molecular weight and degree of deacetylation Pharm Res 21 2 344 353 15032318 10.1023/B:PHAM.0000016249.52831.a5 1:CAS:528:DC%2BD2cXhtlWqtr4%3D (Pubitemid 38221982)
34. M Huang Z Ma E Khor LY Lim 2002 Uptake of FITC-chitosan nanoparticles by A549 cells Pharm Res 19 10 1488 1494 12425466 10.1023/A:1020404615898 1:CAS:528:DC%2BD38XnsFSgsbg%3D (Pubitemid 35266553)
35. P Calvo C Remunan-Lopez JL Vila-Jato MJ Alonso 1997 Chitosan and chitosan/ethylene oxide-propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines Pharm Res 14 10 1431 1436 9358557 10.1023/A:1012128907225 1:CAS:528:DyaK2sXntFeht7g%3D (Pubitemid 27481075)
36. Q Gan T Wang C Cochrane P McCarron 2005 Modulation of surface charge, particle size and morphological properties of chitosan-TPP nanoparticles intended for gene delivery Colloids Surf B Biointerfaces 44 2-3 65 73 16024239 10.1016/j.colsurfb.2005.06.001 1:CAS:528:DC%2BD2MXntVCqu78%3D (Pubitemid 41111534)
37. Y Zheng W Yang C Wang J Hu S Fu L Dong, et al. 2007 Nanoparticles based on the complex of chitosan and polyaspartic acid sodium salt: preparation, characterization and the use for 5-fluorouracil delivery Eur J Pharm Biopharm 67 3 621 631 17533123 10.1016/j.ejpb.2007.04.007 1:CAS:528:DC%2BD2sXhtF2qsL3F (Pubitemid 47576611)
38. NM Zaki ND Mortada GA Awad SS Abd ElHady 2006 Rapid-onset intranasal delivery of metoclopramide hydrochloride part II: safety of various absorption enhancers and pharmacokinetic evaluation Int J Pharm 327 1-2 97 103 16959453 10.1016/j.ijpharm.2006.07.038 1:CAS:528:DC%2BD28XhtFKhsb3P (Pubitemid 44755246)
39. NM Zaki N Tirelli 2011 Assessment of nanomaterials cytotoxicity and internalization Methods Mol Biol 695 243 259 21042977 10.1007/978-1-60761-984-0- 16 1:CAS:528:DC%2BC3cXhsFyru7vJ
40. T Mosmann 1983 Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J Immunol Methods 65 1-2 55 63 6606682 10.1016/0022-1759(83)90303-4 1:STN:280:DyaL2c%2FovFSmtw%3D%3D (Pubitemid 14203433)
41. D Fischer Y Li B Ahlemeyer J Krieglstein T Kissel 2003 In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis Biomaterials 24 7 1121 1131 12527253 10.1016/S0142-9612(02)00445-3 1:CAS:528:DC%2BD3sXis1Smsg%3D%3D (Pubitemid 36069121)
42. Z Zhang S Huey Lee SS Feng 2007 Folate-decorated poly(lactide-co- glycolide)-vitamin E TPGS nanoparticles for targeted drug delivery Biomaterials 28 10 1889 1899 17197019 10.1016/j.biomaterials.2006.12.018 (Pubitemid 46137995)
43. P Tang V Foubister MG Pucciarelli BB Finlay 1993 Methods to study bacterial invasion J Microbiol Methods 18 227 240 10.1016/0167-7012(93)90038-J (Pubitemid 23319452)
44. B Bretschneider M Brandsch R Neubert 1999 Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux Pharm Res 16 1 55 61 9950279 10.1023/A:1018814627484 1:CAS:528: DyaK1MXmtlGmsQ%3D%3D (Pubitemid 29047457)
45. H Saitoh C Gerard BJ Aungst 1996 The secretory intestinal transport of some beta-lactam antibiotics and anionic compounds: a mechanism contributing to poor oral absorption J Pharmacol Exp Ther 278 1 205 211 8764353 1:CAS:528:DyaK28XktlGgs7o%3D (Pubitemid 27167097)
46. H Saitoh H Fujisaki BJ Aungst K Miyazaki 1997 Restricted intestinal absorption of some beta-lactam antibiotics by an energy-dependent efflux system in rat intestine Pharm Res 14 5 645 649 9165537 10.1023/A:1012113430539 1:CAS:528:DyaK2sXjtlSks7c%3D (Pubitemid 27220284)
47. H Saitoh BJ Aungst M Tohyama Y Hatakeyama K Ohwada M Kobayashi, et al. 2002 In vitro permeation of beta-lactam antibiotics across rat jejunum and its correlation with oral bioavailability in humans Br J Clin Pharmacol 54 4 445 448 12392595 10.1046/j.1365-2125.2002.t01-1-01672.x 1:CAS:528:DC%2BD38XpsVWitLY%3D (Pubitemid 35334960)
48. A Nasti NM Zaki P de Leonardis S Ungphaiboon P Sansongsak MG Rimoli, et al. 2009 Chitosan/TPP and chitosan/TPP-hyaluronic acid nanoparticles: systematic optimisation of the preparative process and preliminary biological evaluation Pharm Res 26 8 1918 1930 19507009 10.1007/s11095-009-9908-0 1:CAS:528: DC%2BD1MXmvFGnsbo%3D
49. Yadav AV, Bhise SB. Chitosan: a potential biomaterial effective against typhoid current science. Curr Sci 2004;87(9):1176-1178. (Pubitemid 40374430)
50. EI Rabea ME Badawy CV Stevens G Smagghe W Steurbaut 2003 Chitosan as antimicrobial agent: applications and mode of action Biomacromolecules 4 1457 1465 14606868 10.1021/bm034130m 1:CAS:528:DC%2BD3sXmvVGgt78%3D (Pubitemid 37455555)
51. Y Wu W Yang C Wang J Hu S Fu 2005 Chitosan nanoparticles as a novel delivery system for ammonium glycyrrhizinate Int J Pharm 295 1-2 235 245 15848008 10.1016/j.ijpharm.2005.01.042 1:CAS:528:DC%2BD2MXjtl2rsrg%3D (Pubitemid 40558806)
52. Oyarzun-Ampuero FA, Brea J, Loza MI, Torres D, Alonso MJ. Chitosan-hyaluronic acid nanoparticles loaded with heparin for the treatment of asthma. Int J Pharm 2009;381:122-129.
53. FC MacLaughlin RJ Mumper J Wang JM Tagliaferri I Gill M Hinchcliffe, et al. 1998 Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery J Control Release 56 1-3 259 272 9801449 10.1016/S0168-3659(98)00097-2 1:CAS:528:DyaK1cXntVGhu70%3D (Pubitemid 28511146)
54. DY Zhang XZ Shen JY Wang L Dong YL Zheng LL Wu 2008 Preparation of chitosan-polyaspartic acid-5-fluorouracil nanoparticles and its anti-carcinoma effect on tumor growth in nude mice World J Gastroenterol 14 22 3554 3562 18567086 10.3748/wjg.14.3554 1:CAS:528:DC%2BD1cXhtFOms7rP
55. Q Gan T Wang 2007 Chitosan nanoparticle as protein delivery carrier-systematic examination of fabrication conditions for efficient loading and release Colloids Surf B Biointerfaces 59 1 24 34 17555948 10.1016/j.colsurfb.2007.04.009 1:CAS:528:DC%2BD2sXnsFKktro%3D (Pubitemid 47016920)
56. T Kean S Roth M Thanou 2005 Trimethylated chitosans as non-viral gene delivery vectors: cytotoxicity and transfection efficiency J Control Release 103 3 643 653 15820411 10.1016/j.jconrel.2005.01.001 1:CAS:528:DC%2BD2MXjt1aht7k%3D (Pubitemid 40471022)
57. O Harush-Frenkel N Debotton S Benita Y Altschuler 2007 Targeting of nanoparticles to the clathrin-mediated endocytic pathway Biochem Biophys Res Commun 353 1 26 32 17184736 10.1016/j.bbrc.2006.11.135 1:CAS:528: DC%2BD2sXht1Sgtg%3D%3D (Pubitemid 44958337)
58. JK Vasir V Labhasetwar 2007 Biodegradable nanoparticles for cytosolic delivery of therapeutics Adv Drug Deliv Rev 59 8 718 728 17683826 10.1016/j.addr.2007.06.003 1:CAS:528:DC%2BD2sXpvFWmtrc%3D (Pubitemid 47320811)
59. H Yuan J Miao Y-Z Du J You F-Q Hu S Zeng 2008 Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells Int J Pharm 348 1-2 137 145 17714896 10.1016/j.ijpharm.2007.07.012 1:CAS:528:DC%2BD2sXhsVGlurvK (Pubitemid 350266242)
60. C Coester P Nayyar J Samuel 2006 In vitro uptake of gelatin nanoparticles by murine dendritic cells and their intracellular localisation Eur J Pharm Biopharm 62 3 306 314 16316749 10.1016/j.ejpb.2005.09.009 1:CAS:528: DC%2BD28Xit1Chu70%3D (Pubitemid 43356580)
61. A de Enriquez Salamanca Y Diebold M Calonge C Garcia-Vazquez S Callejo A Vila, et al. 2006 Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance Invest Ophthalmol Vis Sci 47 4 1416 1425 10.1167/iovs.05-0495 (Pubitemid 46780748)
62. NM Zaki A Nasti N Tirelli 2011 Nano-carriers for cytoplasmic delivery: cellular uptake and intracellular fate of chitosan and hyaluronic acid-coated chitosan nanoparticles in a phagocytic cell model Macromol Biosci 11 1747 1760 21954171 10.1002/mabi.201100156 1:CAS:528:DC%2BC3MXhsFyns7rI
63. PJ Van den Broek 1991 Activity of antibiotics against microorganisms ingested by mononuclear phagocytes Eur J Clin Microb Infect Dis 10 114 118 10.1007/BF01964422
64. P Lutwyche C Cordeiro DJ Wiseman M St-Louis M Uh MJ Hope, et al. 1998 Intracellular delivery and antibacterial activity of gentamicin encapsulated in pH-sensitive liposomes Antimicrob Agents Chemother 42 10 2511 2520 9756749 1:CAS:528:DyaK1cXms1Cqurk%3D (Pubitemid 28462887)
65. J Panyam V Labhasetwar 2004 Targeting intracellular targets Curr Drug Deliv 1 3 235 247 16305387 10.2174/1567201043334768 1:CAS:528: DC%2BD2cXkvVyrtLc%3D
66. SS Davis L Illum 2003 Absorption enhancers for nasal drug delivery Clin Pharmacokinet 42 13 1107 1128 14531723 10.2165/00003088-200342130-00003 1:CAS:528:DC%2BD3sXpsF2ls7s%3D (Pubitemid 37357648)
67. G Di Colo S Burgalassi Y Zambito D Monti P Chetoni 2004 Effects of different N-trimethyl chitosans on in vitro/in vivo ofloxacin transcorneal permeation J Pharm Sci 93 11 2851 2862 15389666 10.1002/jps.20197 (Pubitemid 39506634)
68. J Kowapradit P Opanasopit T Ngawhiranpat A Apirakaramwong T Rojanarata U Ruktanonchai, et al. 2008 Methylated N-(4-N, N-dimethylaminobenzyl) chitosan, a novel chitosan derivative, enhances paracellular permeability across intestinal epithelial cells (Caco-2) AAPS PharmSciTech 9 4 1143 1152 19009354 10.1208/s12249-008-9160-7 1:CAS:528:DC%2BC3cXovFanu74%3D
69. S Mao X Shuai F Unger M Simon D Bi T Kissel 2004 The depolymerization of chitosan: effects on physicochemical and biological properties Int J Pharm 281 1-2 45 54 15288342 10.1016/j.ijpharm.2004.05.019 1:CAS:528:DC%2BD2cXmtFCmurc%3D (Pubitemid 39024262)
70. NM Zaki N Tirelli 2010 Gateways for the intracellular access of nano-carriers: a review of receptor-mediated endocytosis mechanisms and of strategies in receptor targeting Expert Opin Drug Deliv 7 8 895 913 20629604 10.1517/17425247.2010.501792 1:CAS:528:DC%2BC3cXptFGku74%3D
71. AM Sadeghi FA Dorkoosh MR Avadi P Saadat M Rafiee-Tehrani HE Junginger 2008 Preparation, characterization and antibacterial activities of chitosan, N-trimethyl chitosan (TMC) and N-diethylmethyl chitosan (DEMC) nanoparticles loaded with insulin using both the ionotropic gelation and polyelectrolyte complexation methods Int J Pharm 355 1-2 299 306 18206322 10.1016/j.ijpharm. 2007.11.052 1:CAS:528:DC%2BD1cXkt1ygsLg%3D
72. HK No NY Park SH Lee SP Meyers 2002 Antibacterial activity of chitosans and chitosan oligomers with different molecular weights Int J Food Microbiol 74 1-2 65 72 11929171 10.1016/S0168-1605(01)00717-6 1:CAS:528:DC%2BD38XhslSqt7Y%3D (Pubitemid 34203704)
73. D Raafat K von Bargen A Haas HG Sahl 2008 Insights into the mode of action of chitosan as an antibacterial compound Appl Environ Microbiol 74 12 3764 3773 18456858 10.1128/AEM.00453-08 1:CAS:528:DC%2BD1cXnvFWlsLs%3D (Pubitemid 351874908)